A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea

Conditions

Carcinoid Syndrome, Neuroendocrine Tumors

Brief summary

The purpose of the protocol is to to assess subject's overall satisfaction regarding control of diarrhea. The study aims to supplement results obtained through clinical trials with data obtained from a population of patients receiving treatment with Somatuline Autogel in routine practice.

Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Atlan P, Caplin ME, SYMNET study group.

2016-01-1536 citations

10.1016/j.dld.2015.12.013

Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study.

Philippe Ruszniewski, Martyn Caplin, Juan W. Valle, Catherine Lombard‐Bohas, Graeme J. Poston et al. (12 authors)

Journal of Clinical Oncology2014-05-20

10.1200/jco.2014.32.15_suppl.4111

Patient-reported satisfaction with symptom control during lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients: Symnet, a large multinational, cross-sectional, observational study.

Philippe Ruszniewski, Martyn Caplin, Juan W. Valle, C. Lombard Bohas, Pascal Maisonobe et al. (7 authors)

Journal of Clinical Oncology2014-01-207 citations

10.1200/jco.2014.32.3_suppl.273

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Out-patients 18 years of age and older, who have agreed to participate in the study * Diagnosed with a Neuroendocrine tumour (NET) and receiving treatment with Somatuline Autogel

Exclusion criteria

* Subjects for whom there are reasons that may hinder the conduct of the study (patients who have difficulty expressing themselves or who are unable to complete the questionnaires, or with insufficient data in the their files will not be enrolled in the study).

Design outcomes

Primary

Measure	Time frame	Description
Subject's overall satisfaction regarding control of diarrhea	Day of survey	Use of questionnaires to assess patient satisfaction (Likert scale).

Secondary

Measure	Time frame	Description
Impact on daily activities of the clinical manifestations of diarrhea	Day of survey	Use of questionnaires to assess symptom severity and impact on patient's daily activities (CGI-S).

Countries

Czechia, France, Hungary, Israel, Italy, Poland, Spain, United Kingdom

Outcome results